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Introduction
TLR3 on endosomes recognizes double-stranded RNA (dsRNA) 
intermediates or by-products generated during viral infection. 
TLR3 signaling leads to the activation of IFN regulatory factor 3 
(IRF3), NF-κB, and ATF/c-jun, promoting the induction of antivi-
ral IFNs and downstream IFN-stimulated genes (ISGs) (1–4). The 
discovery of inborn errors of human TLR3 and its pathway in chil-
dren with herpes simplex virus 1 (HSV-1) encephalitis (HSE) led 
to the suggestion that TLR3 serves as a key sensor for HSV-1 rep-
lication in the CNS (5–7). Childhood HSE is a rare, sporadic, and 
life-threatening complication of primary infection with HSV-1 in 
which the virus replicates in the CNS. HSV-1 infection is ubiqui-
tous in the general population. The virus resides in the trigeminal 
(TG) ganglion, where it remains latent, but can later reactivate to 
cause benign herpes labialis or other rare complications, includ-
ing HSE (8). The pathogenesis of HSE remained unexplained until 
our description of the first genetic etiologies for this disease (9, 
10). Germline HSE-causing mutations have since been reported 
in 7 genes of the TLR3 pathway (TLR3, UNC93B1, TRIF, TRAF3, 
TBK1, IRF3, NEMO) and 2 genes of the IFN-α/β receptor path-
way (IFNAR1, STAT1) (9–17). UNC-93B is a membrane-bound 
molecule that regulates the signaling of endosomal TLR3, TLR7, 
TLR8, and TLR9 by binding to their transmembrane domains and 
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largely on the cGAS DNA sensor in mouse fibroblasts and myeloid 
cells (30), whereas VSV recognition in mouse fibroblasts is depen-
dent on RIG-I (31). It therefore remained unclear whether TLR3 
actually recognizes dsRNA intermediates or by-products gener-
ated during the infection of fibroblasts and cortical neurons with 
HSV-1 and VSV, or whether it controls the IFN-mediated immunity 
of these cells against these viruses by other mechanisms. As a 
first step toward addressing this question, we performed a com-
prehensive analysis of the connection between IFN induction and 
VSV infection in human fibroblasts. We then investigated whether 
our findings also applied to HSV-1 infection in iPSC-derived 
cortical and TG neurons.
Results
RIG-I–dependent overproduction of IFN-β and -λ in response to VSV-
M51R in TLR3-deficient fibroblasts. In human fibroblasts, high lev-
els of mRNA for IFN-β and IFN-λ (including all 3 types of IFN-λ, 
IFNL1, IFNL2, and IFNL3), but not other subtypes of antiviral IFNs, 
can be induced by extracellular poly(I:C) stimulation, which acti-
vates TLR3 in endosomes (Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI134529DS1), or intracellular poly(I:C) stimulation, which acti-
vates RIG-I and MAD5 in the cytosol (Supplemental Figure 1) (28). 
We hypothesized that, if the higher levels of viral growth and cell 
death observed in TLR3-deficient cells were due to an impairment 
of virus-induced IFN production, then a potent IFN-inducing 
stimulus would rescue viral susceptibility. We made use of a natu-
ral mutant of VSV, VSV-M51R, which induces IFN very strongly in 
most of the cells tested, much more so than VSV-WT (32, 33). We 
first assessed the production of IFN-β and -λ following infection 
with VSV-WT and -M51R at various MOIs for 24 hours, in simi-
an virus 40 (SV-40) T antigen–transformed fibroblasts (SV-40 
fibroblasts) from a healthy control, a patient with HSE with auto-
somal recessive (AR) UNC-93B deficiency (UNC-93B–/–), and a 
patient with HSE with AR TLR3 deficiency (TLR3–/–). Surprisingly, 
UNC-93B–/– and TLR3–/– cells produced about 30 times more 
IFN-β than healthy control cells after 24 hours of infection with 
VSV-M51R at a MOI of 0.01 (Figure 1A). Similar results were 
obtained for IFN-λ (as measured by ELISA, which recognizes all 
IFN-λ1/2/3 in a nonspecific manner, Supplemental Figure 2, A 
and B). NEMO–/– fibroblasts displayed no activation of the tran-
scription factors IRF3 and NF-κB in response to viral infection 
(11, 32), and were thus included as a negative control (Figure 1A). 
Consistently, IFNB and IFNL1 mRNA levels were higher in UNC-
93B–/– and TLR3–/– cells than in healthy control cells 24 hours after 
infection with VSV-M51R or -WT (Figure 1B, Supplemental Figure 
2C), although no IFN-β or IFN-λ was detected by ELISA in UNC-
93B–/– and TLR3–/– cells following VSV-WT infection (Figure 1A, 
Supplemental Figure 2A). In UNC-93B–/– and TLR3–/– fibroblasts, 
the response to TLR3 stimulation with extracellularly added 
poly(I:C) was completely abolished, whereas the responses to 
transfection with poly(I:C) (a nonspecific agonist of RIG-I and 
MDA5) and 7sk-as (a specific agonist of RIG-I) were intact (Figure 
1A, Supplemental Figure 3, A–C) (9, 10). IFN induction in response 
to VSV may be RIG-I dependent, as suggested by previous stud-
ies on mouse embryonic fibroblasts (MEFs) (28, 31, 33). Indeed, 
following the short-hairpin RNA–mediated (shRNA- mediated) 
maintaining TLR3 expression (18–21). TRIF is the sole adaptor 
of TLR3, whereas TRAF3, TBK1, IRF3, and NEMO are key mol-
ecules required for the TLR3-TRIF–dependent induction of anti-
viral IFNs (7). Candidate mutations in other genes of the pathway 
have also been reported (22). Mutations of TLR3 pathway genes 
have been shown to impair the TLR3-dependent induction of anti-
viral IFNs, whereas IFNAR1 and STAT1 mutations impair cellular 
responses to type I IFNs. Collectively, these findings suggest that 
HSE can result from the impaired production of IFN-α/β and/or 
IFN-λ in response to TLR3 stimulation by HSV-1 in the CNS.
This hypothesis was initially supported by experiments con-
ducted in dermal fibroblasts infected with HSV-1 and another 
neurotropic virus, vesicular stomatitis virus (VSV), an ssRNA virus 
typically innocuous in humans, chosen for these studies because it 
is highly cytopathic and induces IFN more effectively than HSV-1 
in these cells (23). Fibroblasts with TLR3 signaling deficiencies 
display impaired responses to the TLR3 agonist polyinosinic- 
polycytidylic acid (poly(I:C)), a synthetic analog that mimics dsR-
NA by-products and intermediates of viral replication. Following 
infection with HSV-1 or VSV, TLR3 pathway–deficient fibroblasts 
produce less IFN-β and -λ than control cells, and display higher 
rates of viral replication and virus-induced cell death (9–11, 13–16, 
24). Moreover, the viral phenotype of fibroblasts from patients 
with mutations of TLR3 pathway genes is rescued by pretreat-
ment with IFN-α or -β, but not IFN-λ (9–11, 13–16, 24). The viral 
phenotype of fibroblasts from patients not responding to IFN-α/β 
and -λ due to STAT1 deficiency is not rescued by any type of IFN 
(10). We have also shown that cortical neurons and oligodendro-
cytes derived from TLR3-deficient induced pluripotent stem cells 
(iPSCs) display impaired IFN responses to poly(I:C) and HSV-1, 
and do not control HSV-1, with this viral phenotype being rescued 
by pretreatment with IFN-α or -β but not IFN-λ (25). Collectively, 
these findings suggest that the viral (HSV-1 and VSV) and IFN-β 
phenotypes of TLR3-deficient fibroblasts observed in vitro are a 
surrogate for that of iPSC-derived cortical neurons in vitro and 
predisposition to HSE in vivo.
Unlike iPSC-derived cortical neurons, iPSC-derived periph-
eral TG neurons from healthy donors control HSV-1 as poorly as 
poly(I:C)-unresponsive TLR3-deficient TG neurons, in terms of 
viral growth (26). Pretreatment with IFN-α or -β, but not IFN-λ, 
rescues susceptibility to viral infections in both types of TG neu-
rons, whereas pretreatment with poly(I:C) rescues only control 
TG neurons, in which IFNs and ISGs are induced in response to 
TLR3-dependent poly(I:C) stimulation. These data indicate that 
TG neurons are vulnerable to HSV-1 in the absence of preemp-
tive stimulation via TLR3 or IFN-α/β receptors, whereas control 
cortical neurons display TLR3-dependent constitutive resistance 
that is sufficiently strong to block incoming HSV-1 in the absence 
of prior antiviral signals. This experimental observation in vitro 
is consistent with HSV-1 infecting TG neurons and establishing 
latency in these cells, but not in cortical neurons in vivo in most 
individuals (27). Overall, these findings suggest a cellular model 
of HSE with a TLR3-dependent IFN-mediated phenotype in fibro-
blasts and iPSC-derived cortical but not TG neurons. However, 
the molecular basis of these 2 cellular phenotypes in vitro and of 
HSE in vivo remained unexplained. Indeed, although both HSV-1 
and VSV produce dsRNAs (28, 29), HSV-1 recognition depends 
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coinfected fibroblasts with both VSV-WT and VSV-M51R, the high 
levels of IFN-β production induced by the M51R virus were com-
pletely abolished by coinfection with VSV-WT (Supplemental Fig-
ure 3D) (38). This suggests that the inability to block mRNA export 
from the nucleus, and thus, to abolish IFN production by VSV-WT, 
is responsible for this phenomenon rather than the stimulation, 
by VSV-M51R, of an additional signaling pathway different from 
that stimulated by the WT virus (39). However, consistent with 
the high levels of virus-triggered IFN-β and IFN-λ production in 
UNC-93B–/– and TLR3–/– fibroblasts, we detected substantially 
more dsRNA in the cells of patients with UNC-93B and NEMO 
deficiency than in control fibroblasts (Figure 1C), 8 hours after 
VSV-WT or -M51R infection, by Western blotting with anti– 
dsRNA antibody (28). The high levels of dsRNA are also con-
sistent with the previously known rapid VSV-WT replication in 
UNC-93B–/– and TLR3–/– fibroblasts (9, 10, 13), which was con-
firmed by determining VSV glycoprotein (VSV-G) mRNA levels 
by quantitative real-time PCR (RT-qPCR) (Supplemental Figure 
3E). Interestingly, the induction of IFNB mRNA by VSV-WT was 
detectable only at late time points (not at the 6 hour time point) 
(Supplemental Figure 3F), suggesting that viral replication is 
required for IFN induction. Indeed, this enhanced production 
of IFN in UNC-93B–/– and TLR3–/– cells required an actively rep-
licating virus, as the ultraviolet irradiation of VSV-WT and -M51R 
blocked their stimulatory effect (Supplemental Figure 3G). Thus, 
knockdown of RIG-I or its downstream signaling molecule MAVS 
(34–37), the production of IFN-β in response to VSV-M51R infec-
tion, or to transfected poly(I:C) and 7sk-as, was much weaker 
in RIG-I or MAVS-knockdown UNC-93B–/– cells than in those 
transduced with a control scrambled RNA, indicating the essen-
tial role of RIG-I in sensing VSV-M51R (Supplemental Figure 3, A 
and B). Thus, VSV-M51R can induce IFN-β or IFN-λ via RIG-I in 
UNC-93B–/– and TLR3–/– fibroblasts, and, paradoxically, UNC-
93B–/– and TLR3–/– cells respond to VSV-M51R by producing mark-
edly larger amounts of IFN-β and -λ than control cells.
The hyper-IFN response to VSV-M51R in TLR3-deficient fibro-
blasts is triggered by enhanced viral replication. We then investigated 
whether RIG-I was hyperactive in UNC-93B–/– fibroblasts, which 
would account for IFN overinduction as a means of compensating 
for the lack of TLR3 signaling. We overcame the problem of the 
confounding effect of a larger viral stimulus in UNC-93B–/– cells 
by transfecting the fibroblasts with total cellular RNA isolated 
from VSV-WT– or VSV-M51R–infected Vero cells (vRNA). IFN-β 
production levels were almost identical between UNC-93B–/– and 
healthy control cells stimulated by transfection with vRNA (Sup-
plemental Figure 3C). As no viral proteins antagonistic to IFN 
were produced, VSV-WT and VSV-M51R RNA induced IFN-β to 
similar levels (Supplemental Figure 3C). This result suggests that 
the RIG-I pathway is equally active in the cells of patients with 
UNC-93B deficiency and healthy controls. Moreover, when we 
Figure 1. Paradoxical IFN response 
to VSV-M51R infection in fibroblasts 
with TLR3 signaling deficiencies. 
(A) IFN-β production in SV-40–trans-
formed dermal fibroblasts (SV-40 
fibroblasts) left nonstimulated (NS), 
treated with poly(I:C), or infected with 
VSV-WT (WT) or VSV-M51R mutant 
at various MOIs (0.01, 0.1, 1) for 24 
hours, as measured by ELISA. C1 is a 
healthy control. (B) IFN-β mRNA  
levels in fibroblasts left NS or 
infected for 24 hours with VSV-WT 
or -M51R at a MOI of 1. β-glucuro-
nidase mRNA levels were used for 
normalization. The error bars indicate 
SD of biological triplicates from 3 
independent experiments. P values 
were obtained for 1-way ANOVA and 
subsequent Tukey’s multiple compar-
ison tests. (C) dsRNA from VSV-WT– 
and VSV-M51R–infected fibroblasts, 
visualized by electrophoresis in 
1.5% agar gels, blotting onto nylon 
membranes and incubation with a 
monoclonal antibody against dsRNA. 
Ethidium bromide (EtBr) staining of 
the agar gel is shown as a loading 
control. Data from 3 independent 
experiments are shown. **P < 0.01, 
***P < 0.001, ****P < 0.0001.
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kinetics and virus-induced cell death. 
Surprisingly, although VSV-M51R com-
plemented the IFN phenotype, with IFN 
levels even exceeding those observed in 
controls, this potent induction of IFN pro-
duction by the virus did not decrease viral 
replication and cell mortality in TLR3–/– or 
UNC-93B–/– SV-40 fibroblasts upon infec-
tion with VSV-M51R at a MOI of 1, from 
0.5 hour to 24 hours after infection. Both 
the WT and M51R viruses replicated much 
more rapidly in UNC-93B–/– and TLR3–/– 
cells than in control cells, and, by 6 hours 
after infection, there was at least a 100-
fold difference in titer (Figure 2, A and 
B), whereas IFN induction was not readily 
detectable at this time point (Supplemen-
tal Figure 3F). We then measured VSV 
replication, by assessing viral VSV-G RNA 
levels in fibroblasts from patients with 
inborn errors of TLR3 (TLR3, UNC93B1, 
NEMO) or IFN (STAT1, STAT2) immunity 
(40, 41), comparing these levels with 
those in WT control cells. VSV levels were 
markedly higher in the cells of all patients 
16 hours after infection (Figure 2, C and 
D; and Supplemental Figure 4, A and B). 
Moreover, cell death rates were greater in 
UNC-93B–/– cells than in control cells after 
24 hours of VSV-WT or -M51R infection 
(Figure 2, E and F), despite the extremely 
high levels of IFN production following 
infection with VSV-M51R (Figure 1, A and 
B; Supplemental Figure 2, A–C). Thus, 
although the production of larger amounts 
of immunostimulatory viral replication 
intermediates in TLR3 pathway-deficient 
fibroblasts, such as dsRNA (Figure 1C), 
led to enhanced IFN production by the 
patients’ cells upon infection with VSV-
M51R, this enhanced IFN production was 
not sufficient to protect these cells against 
viral replication, which reached very high 
levels before IFN production was induced 
by the virus.
General antiviral defect in fibroblasts 
with deficiencies of the TLR3 and IFN sig-
naling pathways. We then assessed the 
susceptibility of UNC-93B–/– and TLR3–/– fibroblasts to other virus-
es, which may or may not rely on TLR3 for virus-triggered IFN 
induction, by evaluating viral replication and virus-induced cell 
death. We found that another ssRNA virus, human parainfluenza 
virus 3 (hPIV3), like VSV, replicated faster and to higher titers in 
UNC-93B–/– and TLR3–/– cells than in control cells (Figure 3A). 
As a result, viral cytotoxicity was also higher in UNC-93B–/– and 
TLR3–/– fibroblasts (Figure 3B). IFN-β production was similar in 
control and TLR3- or UNC-93B–deficient fibroblasts infected with 
the potent IFN production observed after VSV-M51R infection in 
cells with TLR3 pathway deficiencies was due to the presence of 
large amounts of dsRNA upon infection, rather than hyperactive 
RIG-I signaling.
Uncontrolled VSV-M51R replication and virus-induced cell death 
in TLR3-deficient fibroblasts despite high levels of virus-induced IFN 
production. We then investigated the second cellular phenotype 
related to inborn errors of TLR3 immunity — viral susceptibility — 
in TLR3–/– and UNC-93B–/– fibroblasts. We measured VSV growth 
Figure 2. Unrestricted virus growth and cytotoxicity in fibroblasts with TLR3 signaling deficiencies. 
VSV-WT (A) and VSV-M51R (B) single-cycle replication curves for fibroblasts from healthy controls (C1 and 
C2) and patients with UNC-93B or TLR3 deficiency at a MOI of 1 over 24 hours. Control fibroblasts (C1–C4) 
and TLR3–/–, UNC93B–/–, NEMO–/–, STAT1–/–, and STAT2–/– fibroblasts were infected with VSV-WT (C) and 
VSV-M51R (D) at a MOI of 0.01 for 16 hours. Viral VSV-G RNA levels were then determined by RT-qPCR and 
normalized against C1. Cell mortality following infection with VSV-WT (E) and VSV-M51R (F) at a MOI of 1 
for C1, UNC-93B–/–, and NEMO–/– fibroblasts, as measured by the release of lactate dehydrogenase (LDH) 
at the times indicated, in hours postinfection (hpi). Values are expressed relative to those for uninfected 
cells. Triplicate measurements from 3 independent experiments (A–B, E–F) or representative results from 
3 independent experiments (C–D) are shown. The error bars indicate SD of biological triplicates. P values 
were obtained through log transformation followed by 1-way ANOVA and subsequent Tukey’s multiple 
comparison tests (A–B) or likelihood ratio tests (C–D), by comparing each patient’s fibroblasts with con-
trol fibroblasts, and the respective P value is indicated. *P < 0.05, **P < 0.01, ***P < 0.001.
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IFN pathway–deficient cells than in 
control cells (Figure 3E; and Supple-
mental Figure 4C), 16 hours after 
infection, whereas IFNB and IFNL 
mRNA induction was detected 24 
hours after infection (Supplemental 
Figure 4, D and E). Overall, these 
data indicate that fibroblasts with 
deficiencies of the TLR3 and IFN 
signaling pathways are highly sus-
ceptible to infection with at least 
3 RNA viruses (VSV, hPIV3, and 
EMCV) and one DNA virus (HSV-1), 
despite a high level of IFN produc-
tion induced by VSV-M51R and the 
normal induction of IFN produc-
tion by hPIV3 and EMCV in TLR3 
pathway–deficient cells. This is par-
adoxical, as poor IFN production by 
these cells upon infection with VSV-
WT and HSV-1 had been thought to 
underlie the cellular vulnerability 
to both viruses.
Low basal levels of IFN and 
ISG expression in fibroblasts with 
TLR3-IFN signaling deficiencies. 
Our previous and current data 
show that the prior treatment (but 
not treatment at the time of infec-
tion) of TLR3 signaling–deficient 
fibroblasts with recombinant IFN-
α2b or -β, but not IFN-λ, protects 
them against VSV-WT and -M51R, 
or HSV-1 replication and virus- 
induced cell death (Supplemental 
Figure 5A) (10). In this study, we 
also found that TLR3 signaling–
deficient cells sustained very high 
levels of virus replication before 
the induction of IFN production 
in response to viral infection (Fig-
ure 3E; and Supplemental Figure 
4, C–E). We therefore hypothe-
sized that viral replication might 
be limited in control cells by 
basal levels of IFNs constitutively expressed in a TLR3-de-
pendent manner. We tested this hypothesis, first by assessing 
basal levels of IFN production in unstimulated SV-40 fibro-
blasts. Control fibroblasts secreted higher basal levels of IFN-β 
than TLR3–/– or UNC-93B–/– fibroblasts (Supplemental Figure 
5B). We further determined basal mRNA levels for IFNB, IFNL1 
(IL29), and downstream ISGs, including CXCL10 and IFI44L, in 
unstimulated fibroblasts. Control cells contained larger amounts 
of mRNA for these genes than SV-40 fibroblasts from patients 
with TLR3, UNC93B, or NEMO deficiency (Figure 4, A–D) whose 
TLR3 response signaling was impaired (9, 11, 13). Fibroblasts 
from previously reported patients with IRAK4 or MYD88 defi-
hPIV3 (Figure 3C), probably reflecting intact IFN induction via 
TLR3-independent pathways. We subsequently challenged fibro-
blasts with encephalomyocarditis virus (EMCV), another RNA 
virus that has been shown to induce IFN production in an 
MDA5-dependent manner in MEFs (31, 42), and that, like hPIV3, 
induces normal levels of IFN production in TLR3-deficient human 
fibroblasts (10, 13). EMCV also replicated to high levels in cells 
with TLR3 pathway deficiencies (TLR3, UNC93B1, NEMO) or IFN 
pathway deficiencies (STAT1, STAT2) (Figure 3D). Finally, consis-
tent with our previous reports of enhanced HSV-1 replication in 
TLR3 pathway–deficient fibroblasts (9, 10), we detected higher 
levels of HSV-1 viral ICP27 RNA in TLR3 pathway–deficient or 
Figure 3. High susceptibility to different viruses in TLR3 signaling–deficient cells. (A) hPIV3 single-cycle 
replication curves in fibroblasts from healthy controls (C1 and C2) and patients with UNC-93B or TLR3 deficiency 
over 24 hours. (B) Viability of fibroblasts 48 hours after infection with hPIV3 at the indicated MOIs. (C) IFN-β 
production, measured by ELISA, after 24 or 48 hours of infection with hPIV3 in C1, C2, UNC-93B–/–, and TLR3–/– 
fibroblasts. Control fibroblasts (C1–C4) and TLR3–/–, UNC93B–/–, NEMO–/–, STAT1–/–, and STAT2–/– fibroblasts were 
infected with EMCV (D) or HSV-1-GFP (E) at a MOI of 0.01 for 16 hours. Viral RNA levels were then quantified by 
RT-qPCR, with normalization against the values for C1. Triplicate measurements from 3 independent experi-
ments (A–C) or representative results from 3 independent experiments (D–E) are shown. The error bars indicate 
SD of biological triplicates. P values were obtained through log transformation followed by 1-way ANOVA and 
subsequent Tukey’s multiple comparison tests (A) or likelihood ratio tests, by comparing each patient’s fibro-
blasts with control fibroblasts (D, E), and the respective P values are indicated. *P < 0.05, **P < 0.01 ***P < 0.001.
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ciencies, in which responses to all 
TLRs except TLR3 were impaired, 
displayed normal levels of IFNs and 
ISGs mRNA (Supplemental Figure 
5C). Basal levels of mRNA for IFNB, 
IFNL1, CXCL10, and IFI44L were 
also lower in SV-40 fibroblasts from 
patients with STAT1 and STAT2 defi-
ciency whose IFN response signaling 
is impaired than in control cells (Fig-
ure 4, A–D) (40, 41). The immortaliza-
tion of fibroblasts with SV-40 T anti-
gen has been reported to affect IFN 
immunity (43). We then analyzed the 
transcriptomes of control, TLR3–/–, 
and STAT1–/– primary fibroblasts by 
RNA sequencing (RNA-Seq) to rule 
out the possibility that the apparent-
ly TLR3-IFN signaling–related basal 
levels of IFN and ISG were an SV-40 
fibroblast–specific phenomenon. We 
found that mRNA for 716 fibroblastic 
ISGs, but not IFNs, was detectable in 
control primary fibroblasts in basal 
conditions. mRNA levels were sig-
nificantly lower in both TLR3–/– and 
STAT1–/– primary fibroblasts than in 
control cells for 43 of the 225 differ-
entially expressed ISGs, whereas 13 
ISGs were upregulated in these cells 
relative to control cells (Figure 4E, 
Supplemental Figure 5D, Supplemen-
tal Table 1). An analysis, with DAVID 
software (44), of the 43 ISGs with low 
basal expression levels further con-
firmed the significant downregula-
tion of type I IFN signaling pathway 
genes and antiviral immune genes in 
TLR3–/– and STAT1–/– primary fibro-
blasts (Supplemental Table 2). Thus, 
TLR3 and IFN signaling deficiencies 
have a profound impact on basal 
IFN-β production and ISG expression 
in SV-40–transformed and primary 
fibroblasts in the absence of exoge-
nous stimulation, demonstrating the 
role of TLR3 in maintaining constitu-
tive antiviral gene expression.
Low basal levels of IFN produc-
tion underlie the enhanced viral growth 
in TLR3-deficient fibroblasts. We 
assessed the importance of basal lev-
els of IFN production in control cells, 
by neutralizing the IFNs and assess-
ing the impact of this intervention on 
VSV replication. We cultured UNC-
93B–/–, STAT1–/–, and control SV-40 
Figure 4. Impact of TLR3 signaling deficiencies on basal IFN-related gene expression. mRNA levels of IFNB 
(A), IFNL1 (B), CXCL10 (C), and IFI44L (D) (relative to GAPDH) in unstimulated fibroblasts from healthy controls 
(C1–C4) and individuals deficient for TLR3-IFN signaling, as quantified by RT-qPCR with normalization against 
C1. Representative data from 3 independent experiments are shown. The error bars indicate SDs of triplicate 
measurements. (E) Gene expression profile of the ISGs differentially expressed in patients with STAT1 (blue 
bar) and TLR3 (orange bar) deficiencies, relative to mean expression levels in controls, as assessed by RNA-
Seq. The heatmap shows the log fold-change in ISG expression, with red indicating upregulation and green 
downregulation. P values were obtained for likelihood ratio tests by comparing each patient’s fibroblasts with 
control fibroblasts (A–D), and the respective P values are indicated. **P < 0.01, ***P < 0.001.
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fibroblasts in the presence or absence of neutralizing polyclonal 
antibodies (NAbs) raised against IFN-α, -β and -λ, for 72 hours. We 
measured VSV-WT and VSV-M51R growth kinetics over 24 hours. 
Viral titers were similar in UNC-93B–/– and STAT1–/– fibroblasts with 
and without NAbs. By contrast, the growth of VSV in control fibro-
blasts was greater at 8 and 24 hours after infection in the presence 
of anti-IFN NAbs than in their absence (Figure 5, A and B), sug-
gesting a substantial contribution of basal IFN production, which 
Figure 5. Constitutive IFN-β production in fibroblasts is TLR3 dependent. Replication of VSV-WT (A) and VSV-M51R (B) in fibroblasts from a healthy 
control (C1) or patients with UNC-93B or STAT1 deficiency, cultured in the presence or absence of neutralizing antibodies against IFN-α, -β, and -λ (IFN Nab). 
(C) CXCL10 mRNA levels in unstimulated fibroblasts after treatment with IFN NAb for 24 hours. (D) IFN-β and IFN-λ1 (IL-29) mRNA levels in TLR3–/– fibro-
blasts transfected with WT TLR3, measured by RT-qPCR and normalized against GUS expression. Replication of VSV-WT (E) and VSV-M51R (F) in TLR3–/– 
fibroblasts stably transfected with empty vector (+EV) or WT TLR3 (+TLR3). Replication of VSV-WT (G) and VSV-M51R (H) in UNC-93B–/– fibroblasts stably 
transfected with empty vector or WT UNC-93B (+UNC-93B). Representative results are shown for 3 (A, B, E–H) or 2 (C–D) independent experiments. The error 
bars indicate SDs of biological triplicates (C, D) or the SEM of biological triplicates (A, B, E–H). P values were obtained through log transformation followed by 
1-way ANOVA and subsequent Tukey’s multiple comparison tests, and the respective P values are indicated. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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levels similar to those in a healthy control following the 
expression of WT TLR3 (Figure 5D). In TLR3–/– cells com-
plemented with WT TLR3, replication rates for VSV-WT 
and VSV-M51R were lower than those in nontransfected 
TLR3–/– cells or in TLR3–/– cells transfected with an empty 
vector (Figure 5, E and F). A similar rescue was observed 
in the growth curve of VSV-WT and VSV-M51R in WT 
UNC-93B–expressing UNC-93B–/– fibroblasts (Figure 5, 
G and H). Collectively, these experiments demonstrate 
that a lack of TLR3 signaling results in a deficiency of cell- 
intrinsic, constitutive antiviral IFN responses in fibro-
blasts, leading to early viral replication that may over-
whelm the activity of RIG-I–dependent IFN production, 
which is induced later in response to viral replication.
Basal IFN-β production by control cells restricts viral 
growth. In human fibroblasts, IFNB was the only interfer-
on gene strongly expressed in basal conditions, and only 
IFNB, IFNL1, IFNL2, and IFNL2 displayed a strong induc-
tion of expression upon activation of the TLR3 or MAVS 
pathway (Supplemental Figure 1). However, these cells 
did not express the receptor for type III IFNs (Supplemen-
tal Figure 6A). We hypothesized that the basal production 
of small amounts of IFN-β by healthy control cells can 
rescue the TLR3-deficient cell phenotype. We evaluated 
the effects of basal IFN, by stimulating patients’ SV-40 
fibroblasts with conditioned medium from healthy con-
trol unstimulated cell cultures. This medium effec-
tively decreased the growth of VSV-M51R (Figure 6A) 
and HSV-1 (Figure 6B, Supplemental Figure 6B) at 24 
hours in TLR3–/– and UNC-93B–/– cells from patients, 
to levels below those in cells treated with medium 
from TLR3–/– and UNC-93B–/– fibroblasts, with virus 
titers close to those measured in control cells. More-
over, mRNA levels for ISGs, including CXCL10, MxA, and RIG-I, 
were upregulated in the patients’ fibroblasts by stimulation with 
conditioned medium from healthy controls, but not with condi-
tioned medium from TLR3–/– and UNC-93B–/– fibroblasts (Figure 
6C, Supplemental Figure 6C). Fibroblasts are unable to respond 
to IFN-λ, probably because they lack IFNLR expression (Supple-
mental Figure 6A) (45). However, the pretreatment of TLR3 sig-
was below the limit of detection for ELISA, in limiting viral growth. 
Consistent with this interpretation, basal ISG CXCL10 mRNA 
levels were strongly decreased by NAb treatment (Figure 5C). We 
then rescued TLR3 signaling in TLR3–/– SV-40 fibroblasts by ecto-
pically expressing WT TLR3 to demonstrate the requirement of 
TLR3 signaling for this constitutive antiviral response limiting viral 
replication. Basal levels of IFNB and IL29 mRNA were restored to 
Figure 6. TLR3-dependent constitutive IFN-β production 
restricts VSV growth. (A) TLR3–/– (left panel) and UNC93B–/– 
(right panel) fibroblasts were subjected to pretreatment with 
conditioned medium from unstimulated cell cultures (as 
indicated in parentheses) for 18 hours and infected with VSV-
M51R for 24 hours. VSV-G mRNA levels were then assessed 
by RT-qPCR, with normalization against GAPDH. (B) Similar 
to A, except that HSV-1 GFP was used to infect cells and ICP27 
mRNA levels were measured by RT-qPCR. (C) TLR3–/– (left 
panel) and UNC93B–/– (right panel) fibroblasts were treated 
with conditioned medium, as indicated in parentheses, for 
24 hours and CXCL10 expression was then quantified by 
RT-qPCR. The error bars indicate SDs of biological triplicates 
from 3 independent experiments. P values were obtained for 
likelihood ratio tests, by comparing each patient’s fibroblasts 
treated with conditioned medium from control or patient 
fibroblasts, and the respective P values are indicated. **P < 
0.01, ***P < 0.001, ****P < 0.0001.
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lower in Tlr3–/– MEFs than in Tlr3 WT MEFs for 38 of the 42 ISGs 
differentially expressed in WT and Tlr3–/– MEFs, whereas 4 ISGs 
were more strongly expressed in these cells than in Tlr3 WT 
MEFs (Figure 7A, Supplemental Figure 7A, Supplemental Table 
3). Seven of the 38 ISGs downregulated in Tlr3–/– MEFs were also 
downregulated in TLR3-deficient human fibroblasts, but differ-
ent ISGs were upregulated in mouse and human TLR3-deficient 
fibroblasts (Supplemental Figure 7B, Supplemental Table 4). As 
in human fibroblasts, an analysis of the 38 ISGs downregulated 
in Tlr3–/– MEFs with DAVID software (44) confirmed a significant 
downregulation of type I IFN signaling pathway genes and anti-
viral immune genes (Supplemental Table 5). We confirmed these 
findings by measuring basal levels of expression for several ISGs 
by RT-qPCR. Consistent with the human data, Tlr3–/– MEFs had 
lower levels of mRNA for various ISGs, including Ifit1, Ifit2, and 
Ifit3 (Figure 7B). Finally, we assessed the viral susceptibility of 
MEFs by measuring viral RNA levels after infection with VSV-WT 
and -M51R. Tlr3–/– MEFs were more susceptible to both VSV-WT 
and -M51R than Tlr3 WT MEFs, as high levels of VSV RNA were 
detected in Tlr3–/– MEFs as early as 5 hours after infection (Figure 
7, C and D; Supplemental Figure 7, C and D). These data suggest 
that TLR3 signaling controls constitutive antiviral IFN immunity 
naling–deficient fibroblasts with either IFN-β or IFN-α2b can res-
cue resistance to viral infection, consistent with the relatively high 
levels of IFNAR expression (Supplemental Figure 6A). We found 
that IFN-β NAbs abolished both the protection against VSV-M51R 
growth and ISG induction conferred by the conditioned culture 
medium from control fibroblasts (Supplemental Figure 6, D and 
E), demonstrating that IFN-β is the protective cytokine in this con-
text. STAT1–/– fibroblasts failed to upregulate ISGs when treated 
with conditioned medium from healthy controls (Supplemental 
Figure 6E), suggesting that the IFN signaling pathway is essential 
for the maintenance of basal ISG expression by basal IFN levels. 
Thus, TLR3-dependent, constitutive IFN-β production governs 
intrinsic antiviral immunity in human fibroblasts.
TLR3 also controls constitutive antiviral IFN immunity in mouse 
fibroblasts. We investigated whether TLR3-dependent constitu-
tive IFN responses also governed cell-intrinsic constitutive antivi-
ral immunity in MEFs. In mice, spontaneous IFN-α/β production 
in vivo in the absence of viral infection primes and enhances the 
immune response (46–48). We performed RNA-Seq on WT pri-
mary MEFs and Tlr3–/– MEFs to determine whether TLR3 plays 
a critical role in controlling cell-intrinsic basal IFN and antiviral 
immunity in mouse cells. Basal mRNA levels were significantly 
Figure 7. TLR3 ablation decreas-
es ISG expression and increases 
vulnerability to viruses in 
MEFs. (A) Gene expression 
profile of all differentially 
expressed ISGs in Tlr3–/– MEFs 
relative to mean levels in WT 
mice, as assessed by RNA-
Seq. The heatmap shows the 
log fold-changes of ISG gene 
expression, with red indicating 
upregulation and green down-
regulation. (B) ISG expression 
was assessed in unstimulated 
WT and Tlr3–/– MEFs, by RT-qP-
CR with normalization against 
RPL19. WT and Tlr3–/– MEFs 
were infected with VSV-WT (C) 
and VSV-M51R (D) for 24 hours. 
Viral RNA levels were then 
quantified by RT-qPCR, with 
normalization against RPL19. 
The error bars indicate SDs of 
technical triplicates.
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binant IFN-α2b or -β, but not IFN-λ, protected them against HSV-1 
replication (25, 26). We investigated whether our findings for fibro-
blasts also applied to cortical and TG neurons. We derived cortical 
and TG neurons from one healthy control iPSC line, one healthy 
hESC line, an iPSC line from a patient with AR complete TLR3 
deficiency (26), and an isogenic TLR3-KO iPSC line that we gener-
ated by CRISPR/Cas9-mediated gene editing (Supplemental Fig-
ure 8, A and B) (49). As in SV-40 fibroblasts, virus-induced IFNB 
and IFNL1 induction occurred late, 16 and 24 hours after HSV-1 
infection (Supplemental Figure 8, C and D). When cortical neurons 
in both mouse and human fibroblasts, which use this mechanism 
to restrict infection with various viruses.
Impaired basal IFN-β and intrinsic antiviral immunity in 
TLR3-deficient iPSC-derived cortical but not TG neurons. We pre-
viously showed that TLR3 deficiency impairs cell-autonomous 
defense against HSV-1 infection in iPSC-derived cortical neurons 
and oligodendrocytes, but not astrocytes, neural stem cells, and 
TG neurons (25, 26). As with fibroblasts, prior treatment (but not 
treatment at the time of infection) of TLR3 pathway–deficient 
iPSC-derived cortical neurons and oligodendrocytes with recom-
Figure 8. TLR3 controls basal IFN-β and 
antiviral immunity in cortical neurons. 
HPSC-derived cortical neurons from 2 
control lines (hESC control, iPSC control), 
a CRISPR/Cas9-mediated TLR3 knockout 
(TLR3-KO) line, and a TLR3–/– patient line 
were infected with VSV-WT (A), VSV-M51R 
(B), or HSV-1 (C) for the indicated times. 
Viral replication was assessed in 50% TCID50 
assays. (D) IFN-β levels were measured 
in the culture supernatants of hPSC-de-
rived cortical neurons, by Simoa digital 
ELISA. (E) Gene expression profile of the 
ISGs differentially expressed in patients 
with TLR3 (orange bar) and STAT1 (blue 
bar) deficiencies, relative to controls, as 
assessed by RNA-Seq. (F) Gene expression 
profile of the ISGs differentially expressed 
in TLR3-KO iPSC-derived cortical neurons, 
relative to parental control iPSC-derived cor-
tical neurons. The heatmap shows the log 
fold-change in ISG expression, as assessed 
from 2 technical duplicates of the RNA-Seq, 
with red indicating upregulation and green 
downregulation. The error bars indicate the 
SEM (A–C) or SDs (D) of biological triplicates 
from 3 independent experiments. P values 
were obtained with (A–C) or without (D) log 
transformation followed by 1-way ANOVA 
and subsequent Tukey’s multiple compari-
son tests, by comparing TLR3–/– or TLR3-KO 
cortical neurons with controls, and the 
respective P values are indicated. *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001.
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tion contrasts with that in healthy control fibroblasts, in which VSV 
replication and cell death are limited by basal IFN-β levels, which 
are higher not only than those in UNC-93B–/– and TLR3–/– cells, but 
also than those in NEMO–/–, STAT1–/–, and STAT2–/– cells. In human 
fibroblasts lacking TLR3 signaling (e.g., UNC-93B–/–, TLR3–/–, 
NEMO–/–), the impairment of constitutive low-level TLR3-depen-
dent IFN-β production may reduce the responsiveness and intrin-
sic defenses of uninfected cells against viral infection, by reducing 
the basal level of expression of specific ISGs. In cells lacking IFN 
signaling responses (e.g., STAT1–/–, STAT2–/–), impaired responses 
to IFN-β result in lower levels of basal expression for ISGs, includ-
ing TLR3 and STAT1. As a more general consequence, fibroblasts 
lacking TLR3 and IFN signaling are highly susceptible to infection 
with the 3 RNA viruses (VSV, hPIV3, EMCV) and the DNA virus 
(HSV-1) tested, regardless of the levels of IFN-β induction by these 
viruses. Similarly, TLR3-deficient iPSC-derived cortical neurons 
are highly susceptible to infection with VSV and HSV-1. Collec-
tively, our data indicate that inborn errors of the TLR3 pathway 
impair basal and protective IFN-β antiviral immunity in human 
fibroblasts and cortical neurons.
We have shown that this TLR3 rheostat also operates in mouse 
fibroblasts. Previous studies have shown that Tlr3–/– mice are no 
more susceptible than their WT littermates to VSV, lymphocytic 
choriomeningitis virus, or reovirus (53), and that they are even 
more resistant to Punta Toro virus (54), influenza virus (55), and 
vaccinia virus (56). Mouse fibroblasts may not have been infected 
in the course of such experiments, or their contribution to host 
defense may be compensated by other cells. However, mouse 
TLR3 is required for antiviral immunity to mouse cytomegalovirus 
(57), respiratory syncytial virus (58), coxsackievirus group B sero-
type 3 (CVB3) (59), and coxsackievirus B4 (CVB4) viruses (60). 
The contribution of fibroblasts in these models is unknown. Other 
cell types in mice may also control basal IFN-β immunity through 
TLR3. Interestingly, the DNA sensor cGAS controls basal levels 
of IFNs and ISGs in mouse bone marrow–derived macrophages 
(61). It is therefore possible that TLR3 and cGAS control basal 
ISG levels in different cell types. In certain cell types, both may 
be required for basal antiviral immunity. Mouse cGAS is essential 
for defense against various infections, including HSV-1 infection 
(30). The genetic ablation of cGAS revealed that this protein was 
required for antiviral responses to both DNA viruses and RNA 
viruses in vivo (61). Future studies with single and double knock-
outs of TLR3 and cGAS in mice and humans may delineate the 
respective contributions of TLR3 and cGAS, as viral sensors versus 
rheostats of IFN immunity in host defense. Virus-induced IFN-α/β 
and IFN-λ production could be protective against viral infection in 
vivo, probably following the earliest stage of viral infection. The 
study of MDA5 and RIG-I in this context is also warranted by the 
identification of patients with MDA5 deficiency displaying selec-
tive vulnerable to respiratory viruses (62, 63). The identification of 
patients with cGAS, STING, or RIG-I deficiency could provide new 
insight into this aspect.
The natural TLR3 stimuli controlling basal IFN-β produc-
tion in fibroblasts and cortical neurons remain unknown. In the 
absence of exogenous stimulation, endogenous ligands such as 
mRNAs or debris from necrotic cells can trigger TLR3 signaling in 
human dendritic cells (64) and murine macrophages (65), respec-
were infected with VSV-WT, VSV-M51R, and HSV-1, higher levels 
of viral replication were observed as early as 6 hours after infec-
tion in TLR3-deficient cells, confirming that TLR3 is essential for 
the control of HSV-1 in these cells, and showing that this receptor 
is also essential for control of the 2 types of VSV tested (Figure 8, 
A–C). By contrast, the replication of the 3 viruses was not higher 
in TG neurons lacking TLR3 than in the other cells (Supplemen-
tal Figure 8, E–G). TLR3 protein levels were undetectable in both 
patient-specific and isogenic TLR3-deficient iPSC-derived cortical 
neurons, as shown by Western blotting (Supplemental Figure 8A). 
We also assessed basal IFN-β protein secretion by cortical neurons 
in the Simoa assay (50). We showed that basal levels of IFN-β pro-
duction were low in TLR3-deficient cells (Figure 8D). We further 
analyzed the transcriptomes of control iPSC-derived cortical neu-
rons, comparing them with those of TLR3-deficient patient and 
isogenic TLR3-KO iPSC-derived cortical neurons. Consistent with 
our results for fibroblasts, TLR3-deficient cortical neurons had 
low levels of ISG mRNAs (Figure 8, E and F; and Supplemental 
Figure 9, A and B). The IFN mRNAs themselves were not detected 
by RNA-Seq. In total, we detected the expression of 734 ISGs in 
control cortical neurons in basal conditions. The mRNA levels 
for these genes were significantly lower in both TLR3-deficient 
patient and TLR3-KO cortical neurons than in control cells, for 243 
of 265 and 283 of 311 differentially expressed ISGs, respectively, 
whereas 22 and 28 ISGs were upregulated in these cells relative to 
control cells (Supplemental Figure 9, C and D; and Supplemental 
Table 6). As many as 196 of the downregulated ISGs and 9 of the 
upregulated ISGs were common to TLR3-KO and TLR3-deficient 
patient neurons. An analysis with DAVID software (44) of the 196 
ISGs with low basal levels of expression confirmed the significant 
downregulation of the genes controlled by the IFN-α/β–respon-
sive pathway, and of antiviral genes in both TLR3-KO and TLR3- 
deficient cortical neurons (Supplemental Table 7). Collectively, 
these findings strongly suggest that TLR3 also controls constitu-
tive levels of IFN-β, and thus, cell-intrinsic antiviral immunity, in 
human hPSC-derived cortical neurons. This process is crucial for 
infection control, at least for VSV and HSV-1 in vitro and, by infer-
ence, probably HSV-1 in vivo.
Discussion
We describe an unexpected role of TLR3 signaling in antiviral 
immunity: as a rheostat controlling constitutive low-level pro-
duction of IFN-β, which is crucial for limiting viral replication at 
early stages in the viral infection of dermal fibroblasts and cortical 
neurons. IFN-β was previously thought to be the fibroblastic IFN 
because it was discovered in these cells, in which no other type I 
IFNs were detectable (51). In most other cells, it is the first IFN 
to be induced after viral infection, triggering the amplification 
of other IFNs via IRF7 (52). We discovered that the restriction of 
VSV growth in human fibroblasts was heavily dependent on the 
TLR3-dependent basal IFN-β production of these cells, rather 
than their recognition of VSV and the subsequent RIG-I–depen-
dent induction of IFN-β. Basal IFN-β production is impaired in 
TLR3–/– and UNC-93B–/– fibroblasts, and these cells are therefore 
overwhelmed by VSV-WT and even M51R replication within as 
little as 6 hours after infection, before the RIG-I–dependent induc-
tion of IFN-β production in response to viral infection. This situa-
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infection (80–82). Our findings also suggest that TLR3 may govern 
the first line of broad antiviral responses in some cell types, such 
as fibroblasts, cortical neurons, and perhaps PECs, or even more 
broadly in certain tissues or organs, such as the CNS and lungs in 
particular, as opposed to governing immunity to specific viruses, 
such as HSV-1, in various cells, tissues, and organs.
Methods
Cells and viruses. Primary fibroblasts were isolated from skin biopsy 
specimens from patients with AR UNC-93B, AR STAT1, XR NEMO, 
and AR TLR3 deficiencies and healthy controls, as previously 
described (9, 11, 13, 41). The fibroblasts were immortalized by trans-
fection with the SV-40 large T antigen and maintained in DMEM sup-
plemented with 10% FBS.
Cells stably expressing shRNAs against RIG-I and MAVS were 
generated by transduction with shRNA-expressing retroviral particles 
(Santa Cruz Biotechnology). Stably transfected cell lines were gener-
ated by transfecting TLR3–/– or UNC-93B–/– fibroblasts with TLR3 or 
UNC-93B WT or empty vector, with Lipofectamine 2000 (Invitro-
gen). Transfectants were selected in DMEM containing 5 μg/mL blas-
ticidin (Invitrogen).
VSV, Indiana strain, WT, and M51R mutant (harboring a substi-
tution of an arginine residue in place of the methionine in position 51 
of the matrix (M) protein) were provided by Pierre Lebon and have 
been described elsewhere (10, 39, 83–85). MEFs were generated from 
14-day-old WT and Tlr3−/− embryos (86), and maintained in DMEM 
supplemented with 10% FBS.
Cell culture of iPSCs and hESCs (together referred to as hPSCs), and 
neuronal induction and differentiation. Control MRC5 and TLR3–/– 
patient-specific iPSC lines were reprogrammed with a nonintegrating 
Sendai viral vector, as previously described (26). All hPSC lines were 
used at passage 20–50, and were maintained on vitronectin with 
Essential 8 medium (Fisher Scientific), with twice-weekly passaging 
with EDTA (87). The HPSC lines used here were as follows: TLR3–/– 
patient-specific iPSCs, control iPSCs MRC5, isogenic MRC5 TLR3 KO 
iPSCs, and a control hESC line H9 (WA-09) (26). All cell lines were 
karyotyped to ensure genomic integrity and weekly tests for myco-
plasma were performed. TG neuron and cortical neuron differentia-
tion was performed as previously described (26).
Cell stimulation. SV-40 fibroblasts were plated at a density of 105 
cells per well in a 24-well plate and were incubated overnight. Poly-
inosinic-polycytidylic acid (poly(I:C); Amersham) was added to the 
culture medium at a concentration of 25 μg/mL, transfected with the 
RIG-I agonist, 7sk-as at a concentration of 0.45 ng, or with 25 μg of 
poly(I:C), with Lipofectamine 2000 (Invitrogen), or infection with 
VSV at the indicated MOIs, and the culture medium was harvested 
after 24 hours of stimulation. Cytokine concentrations in culture 
medium were determined by ELISA.
Measurement of cytokine production. IFN-β production was 
assessed in an enzyme-linked immunosorbent assay (ELISA; TFB 
Fujirebio). For IFN-λ determinations, culture supernatants were 
incubated for 2 hours in plates coated with 1 μg/mL monoclonal 
anti-human IL29 antibody (R&D Systems). A biotinylated mono-
clonal secondary antibody directed against human IL-29 (R&D Sys-
tems) and streptavidin peroxidase were added, together with TMB 
(3,3′,5,5′-tetramethylbenzidine). The signal at 450 nm was then read 
with a plate fluorescence reader.
tively. Self-noncoding RNAs generated during cell damage and 
the microtubule regulator stathmin have been identified as endog-
enous agonists of TLR3 in human keratinocytes and in human 
astrocytes and microglia cells, respectively (66, 67). One or more 
of these known cell-endogenous agonists may activate TLR3 in 
fibroblasts, cortical neurons, and other cells, thereby contributing 
to basal IFN and ISG production. However, it remains possible 
that TLR3 can sustain basal activation in the absence of stimula-
tion with any ligand. In any event, our study clearly demonstrates 
that TLR3 is essential for the maintenance of constitutive IFN-β 
immunity in human fibroblasts and cortical neurons, and this 
observation also applies to mouse fibroblasts. It may also operate 
in other CNS-resident cells, such as oligodendrocytes, in which 
the control of HSV-1 is also dependent on TLR3, contrasting with 
the situation in astrocytes, neural stem cells, and TG neurons (25, 
26). Constitutive TLR3 activity in the brain may also be important 
in the prevention of other neurological conditions via mechanisms 
that may or may not be related to IFN-mediated immunity (68, 
69). While we cannot yet discern the respective roles of constitu-
tive and virus-induced cell-intrinsic IFN immunity in the course 
of natural infection with HSV-1 in TLR3-deficient individuals, 
our findings provide a plausible molecular and cellular basis for 
HSE in patients with inborn errors of TLR3 immunity. They also 
suggest that IFN-α/β, rather than IFN-λ, are critical for protective 
immunity to HSV-1 in the CNS.
Our findings also suggest that TLR3-dependent cell-intrinsic 
constitutive IFN immunity may be a critical first line of defense 
against HSV-1 and perhaps other viruses in certain tissues, and its 
disruption may result in tissue-specific severe viral infections in 
various organs. Patients with TLR3 deficiency may also be more 
susceptible to diseases other than HSE. This was confirmed by our 
recent identification of 3 unrelated patients with TLR3 mutations 
and severe influenza pneumonia (70), a finding that is consistent 
with TLR3 being a major IFN-β– and IFN-λ–inducing receptor in 
human and mouse pulmonary epithelium cells (PECs), in which 
large amounts of IFN-λ may be produced with potent antiviral 
activity (70, 71). Furthermore, a deleterious TLR3 mutation has also 
been found in a patient with varicella zoster virus ophthalmic neu-
ritis (72). Overall, our findings indicate that TLR3 controls baseline 
tone of IFN-β and IFN-λ in dermal fibroblasts and of IFN-β in corti-
cal neurons (both cell types respond to IFN-β but not IFN-λ). They 
also suggest that TLR3 may control baseline levels of IFN-β and/
or IFN-λ in PECs (which respond to both IFN-β and IFN-λ). The 
genetic dissection of various viral diseases, including coronavirus 
disease 2019 (COVID-19) (73–75), may help to delineate the roles 
of human TLR3 and other IFN-inducing sensors in host defense. 
It also seems likely that deficiencies of other type I IFN respon-
siveness circuit genes (e.g., IRF7, IRF9, STAT1, STAT2, IFNAR1, 
IFNAR2) render patients prone to a broad spectrum of viral diseas-
es, other than the previously reported phenotypes including severe 
influenza pneumonia (IRF7, IRF9), HSE (IFNAR1, STAT1), and 
severe adverse reactions to live attenuated viral vaccines (IRF9, 
STAT1, STAT2, IFNAR1, IFNAR2) (12, 17, 40, 76–79), partly due to 
the low basal levels of IFN-β, IFN-λ, and ISG in tissue-specific cells. 
Our findings highlight the importance of host cell–intrinsic and 
constitutive, as opposed to pathogen-induced, IFN and ISG immu-
nity in antiviral defenses, particularly during early stages of viral 
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was performed with Applied Biosystems TaqMan assays, using the 
β-glucuronidase (GUS) housekeeping gene for normalization, or in 
SYBR Green assays with the GAPDH (human) or RPL19 (mouse) 
housekeeping gene for normalization. Results are expressed according 
to the ΔΔCt method, as described by the manufacturer.
RNA sequencing and analysis. Total RNA was extracted from 
human primary fibroblasts, C57BL/6 mouse primary fibroblasts, 
or hPSC-derived cortical neurons. RNA samples were treated with 
DNase (Ambion) to remove residual genomic DNA. RNA-Seq libraries 
were prepared with the Illumina RiboZero TruSeq Stranded Total RNA 
Library Prep Kit (Illumina) and sequenced on the Illumina NextSeq 
platform in the 150 nt with paired-end configuration. We sequenced 
3 (human samples) or 2 (mouse samples) technical replicates for each 
sample. The raw sequencing data is available under National Center 
for Biotechnology Information Sequence Read Archive (NCBI-SRA) 
accession number SRP288648.
The RNA-Seq FASTQ raw data were inspected with multiQC 
v1.6 to ensure that they were of high quality (89). The sequencing 
reads of human and mouse samples were mapped onto the UCSC 
human reference genome GRCh37/hg19 and the UCSC mouse refer-
ence genome GRCm38/mm10, respectively (90), with STAR aligner 
v2.6 (91). The quality of each mapped alignment in BAM files was 
evaluated with RSeQC (92). Reads were quantified to determine the 
number of gene-level read counts forming the read alignment, with 
featureCounts v1.6.0 and GENCODE GRCh37.p13 human gene anno-
tation V19 and GENCODE GRCm38.p6 mouse gene annotation M19, 
respectively (93, 94). The gene-level read counts were normalized and 
log2-transformed by DESeq2 to obtain the gene expression value for all 
genes and all samples (95).
We extracted expression data for 905 ISGs based on our previous 
IFN-stimulated microarray data analysis (13). Differential ISG expres-
sion was analyzed by applying TMM normalization and gene-wise 
generalized linear model regression in edgeR (96). The ISGs displaying 
significant differential expression were selected on the basis of a FDR 
< 0.05. We used ComplexHeatmap (97) to plot a heatmap of the fold-
change in gene expression. Gene set enrichment analysis was performed 
with Ingenuity Pathway Analysis (IPA) (98) and DAVID (44) software.
Conditioned medium experiments. Conditioned culture medium was 
harvested from healthy control, TLR3–/–, or UNC-93B–/– unstimulated cell 
cultures after 2 days of culture. Cell debris was removed by centrifuga-
tion. Healthy control, TLR3–/–, UNC-93B–/–, or STAT1–/– fibroblasts were 
then cultured in fresh DMEM. The conditioned culture supplemented 
with 100 U neutralizing antibodies against IFN-β or -α or normal sheep 
serum (isotype control) was added to the culture medium of the cells, 
and was maintained in the medium for 18 hours. RNA was isolated for 
RT-qPCR, and VSV growth was measured at the time points indicated.
Gene editing. Gene-editing experiments were performed as previ-
ously described (99). Briefly, guide RNA (gRNA) sequences were gen-
erated with the CRISPR design tool (http://crispr.mit.edu/). GTCATC-
GAATCAAATTAAAG was selected as the guide sequence. Forward 
and reverse oligonucleotides for each gRNA were then inserted into 
the MLM3636 vector (Addgene, 43860). We electroporated 2 million 
hPSCs with 20 μg of Cas9-GFP plasmid and 5 μg gRNA plasmid mixed 
in electroporation buffer (BTX, catalog 45-0805). Green cells were 
sorted by FACS 48 hours after electroporation. About 50,000 cells 
with a moderate GFP fluorescence intensity were cultured, plated at 
clonal density in 96-well plates, and amplified. Genomic DNA was 
Immunoblotting. Cells were lysed in NP40 lysis buffer (280 mM 
NaCl, 50 mM Tris pH 8, 0.2 mM EDTA, 2 mM EGTA, 10% glycer-
ol, 0.5% NP40) supplemented with 1 mM DTT, 5 mM Na3VO4, and 
Complete protease inhibitor cocktail (Roche). The protein lysate 
was subjected to SDS-PAGE and the bands obtained were trans-
ferred to a PVDF membrane, which was probed with unconjugated 
rabbit anti–RIG-I (Cell Signaling, catalog 3743), goat anti-MAVS 
(Santa Cruz Biotechnology, catalog sc-365333), TLR3 (R&D Sys-
tems, catalog 1487) and HRP-conjugated secondary antibodies. A 
β-tubulin antibody (MilliporeSigma, catalog T4026) and a GAPDH 
(Santa Cruz Biotechnology, catalog sc-365062) antibody were used 
as loading controls.
For the detection of dsRNA in VSV-infected cells, SV-40 fibro-
blasts were infected as described above, with VSV at a MOI of 10 for 
8 hours. RNA was isolated with TRIzol reagent (Invitrogen), accord-
ing to the manufacturer’s protocol. We subjected 30 μg total RNA to 
electrophoresis in a 1.5% agarose/TBE gel, and the bands were then 
transferred to a nylon membrane (Hybond N+, GE Healthcare). The 
RNA was fixed by ultraviolet irradiation, probed with the anti–dsRNA 
antibody K1, and the blot was developed for enhanced chemilumines-
cence (Pico ECL, Pierce).
Viral assays. SV-40–transformed fibroblasts were plated at a 
density of 105 cells per well in 24-well plates. For one-step growth 
curves, the cells were incubated with VSV-WT and -M51R, hPIV3, 
EMCV, or HSV-1 at the indicated MOI for 30 minutes or 1 hour, 
washed twice in PBS, and then transferred to fresh DMEM. Virus 
samples were collected at the indicated times and the viral titer was 
determined by 50% tissue culture infective dose (TCID50) assays 
on Vero E6 cells (for VSV and hPIV3), according to the Reed and 
Muench calculation (13), or by qPCR methods for EMCV (88), deter-
minations of ICP27 mRNA levels for HSV-1, and determinations of 
VSV-G mRNA levels for VSV.
For coinfection experiments, cells were infected with VSV-WT at 
a MOI of 3 and with VSV-M51R at a MOI of 1 in DMEM supplement-
ed with 10% FBS for 24 hours. VSV-WT and -M51R were inactivated 
by exposure to ultraviolet light for 10 minutes at a distance of 15 cm. 
Cytokine production was measured in the culture medium by ELISA.
For IFN neutralization experiments, cells were cultured in the 
presence of neutralizing polyclonal antibodies against IFN-α and -β 
(PBL), replaced daily for 3 days. They were then infected with VSV-WT 
or -M51R at a MOI of 3, as described above. Samples were harvested at 
the times indicated and titered on Vero cells.
Cytotoxicity assays. Cells were plated at a density of 2 × 104 cells 
per well in 96-well plates, in DMEM with or without IFNα2b (105 
IU/mL, Schering-Plough) treatment for 18 hours. The medium was 
replaced with medium containing VSV at the indicated MOIs. Mor-
tality was assessed 24 hours after infection, with the LDH Cytoxicity 
Detection KitPLUS (Roche). The death of cells is expressed relative to 
that of uninfected cells. For hPIV3 infection, fibroblasts were plated 
as above and infected at the indicated MOIs. Viability was assessed 
in a resazurin-based viability assay (MilliporeSigma). The viability of 
infected cells is expressed relative to that of uninfected cells.
Determination of mRNA levels by RT-qPCR. Total RNA was extracted 
from cells with TRIzol (Invitrogen) or the RNeasy kit (QIAGEN). Sam-
ples were treated with DNase at 37°C for 1 hour and cleaned by passage 
through an RNeasy column (QIAGEN). Reverse transcriptase-PCR was 
performed with random hexamers (Applied Biosystems). RT-qPCR 
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